sulbactam-durlobactam
Selected indexed studies
- Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK). (Lancet Infect Dis, 2023) [PMID:37182534]
- Sulbactam/Durlobactam: First Approval. (Drugs, 2023) [PMID:37523122]
- Sulbactam-durlobactam: a β-lactam/β-lactamase inhibitor combination targeting Acinetobacter baumannii. (Future Microbiol, 2024) [PMID:38426849]
_Worker-drafted node — pending editorial review._
Connections
sulbactam-durlobactam is a side effect of
Sources
- Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK). (2023) pubmed
- Sulbactam/Durlobactam: First Approval. (2023) pubmed
- Sulbactam-durlobactam: a β-lactam/β-lactamase inhibitor combination targeting Acinetobacter baumannii. (2024) pubmed
- Cefiderocol and Sulbactam-Durlobactam against Carbapenem-Resistant Acinetobacter baumannii. (2023) pubmed
- Sulbactam and Durlobactam. (2006) pubmed
- Sulbactam/Durlobactam. (2024) pubmed
- Sulbactam-durlobactam for the treatment of Acinetobacter baumannii-calcoaceticus complex. (2024) pubmed
- Sulbactam-durlobactam: A novel β-lactam-β-lactamase inhibitor combination targeting carbapenem-resistant Acinetobacter baumannii infections. (2023) pubmed
- Sulbactam-Durlobactam in the Treatment of Carbapenem-Resistant Acinetobacter baumannii Infections. (2024) pubmed
- Successful Treatment of Carbapenem-Resistant Acinetobacter baumannii Meningitis With Sulbactam-Durlobactam. (2024) pubmed